Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Fluocortolone is a synthetic glucocorticoid corticosteroid used primarily as a moderately potent topical corticosteroid for the treatment of inflammatory skin conditions such as eczema, dermatitis, and psoriasis. It is also indicated for hemorrhoids, anal fissures, dermatoses, and proctitis. Fluocortolone exerts its anti-inflammatory effects by binding to glucocorticoid receptors in target cells (primarily skin cells), forming a steroid-receptor complex that translocates into the nucleus and modulates gene expression. This process inhibits the production of pro-inflammatory proteins while promoting anti-inflammatory proteins, thereby reducing inflammation, itching (pruritus), redness, and pain. The drug can be administered topically or orally; after oral administration up to 15% may be systemically absorbed[1][2][4][5][6][8].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Fluocortolone.